newsfilter
← Earnings
Earnings Releases·

TScan Therapeutics — Third Quarter 2026 Earnings Summary

  • Revenue declined to $0.6 million from $2.5 million year-over-year following the August 2026 termination of the Amgen collaboration agreement, while net loss narrowed to $33.1 million from $35.7 million in the prior year period.
  • Cash and cash equivalents decreased to $73.0 million from $152.4 million at year-end 2025, triggering a two-year term loan amortization in Q4 2026 due to missed non-covenant milestones; existing resources are projected to fund operations through Q4 2027.
  • Strategic reorganization prioritizes the in vivo-engineered TCR-T solid tumor program, with preclinical data and FDA feedback anticipated in Q1 2027 and the first IND filing targeted for Q3 2027.
  • Enrollment in the Phase 3 ALLOHA-2 study for the Heme Malignancies program was paused due to capital constraints, though the company remains committed to tracking enrolled patients and actively seeks strategic partners for this and autoimmunity programs.
Company
TSCAN THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology